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Alterations in phenotype and gene expression of adult human aneurysmal
smooth muscle cells by exogenous nitric oxide
Kurt Farrell, Phillip Simmers, Gautam Mahajan, Ludovic Boytard, Andrew Camardo, Jyotsna 
Joshi, Anand Ramamurthi, Florence Pinet, Chandrasekhar R. Kothapalli
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A B S T R A C T
Abdominal aortic aneurysms (AAA) are characterized by matrix remodeling, elastin degradation, absence of
nitric oxide (NO) signaling, and inflammation, influencing smooth muscle cell (SMC) phenotype and gene ex-
pression. Little is known about the biomolecular release and intrinsic biomechanics of human AAA-SMCs. NO
delivery could be an attractive therapeutic strategy to restore lost functionality of AAA-SMCs by inhibiting
inflammation and cell stiffening. We aim to establish the differences in phenotype and gene expression of adult
human AAA-SMCs from healthy SMCs. Based on our previous study which showed benefits of optimal NO dosage
delivered via S-Nitrosoglutathione (GSNO) to healthy aortic SMCs, we tested whether such benefits would occur
in AAA-SMCs. The mRNA expression of three genes involved in matrix degradation (ACE, ADAMTS5 and
ADAMTS8) was significantly downregulated in AAA-SMCs. Total protein and glycosaminoglycans synthesis were
higher in AAA-SMCs than healthy-SMCs (p < 0.05 for AAA-vs. healthy- SMC cultures) and was enhanced by
GSNO and 3D cultures (p < 0.05 for 3D vs. 2D cultures; p < 0.05 for GSNO vs. non-GSNO cases). Elastin gene
expression, synthesis and deposition, desmosine crosslinker levels, and lysyl oxidase (LOX) functional activity
were lower, while cell proliferation, iNOS, LOX and fibrillin-1 gene expressions were higher in AAA-SMCs
(p < 0.05 between respective cases), with differential benefits from GSNO exposure. GSNO and 3D cultures
reduced MMPs −2, −9, and increased TIMP-1 release in AAA-SMC cultures (p < 0.05 for GSNO vs. non-GSNO
cultures). AAA-SMCs were inherently stiffer and had smoother surface than healthy SMCs (p < 0.01 in both
cases), but GSNO reduced stiffness (~25%; p < 0.01) and increased roughness (p < 0.05) of both cell types. In
conclusion, exogenously-delivered NO offers an attractive strategy by providing therapeutic benefits to AAA-
SMCs.
1. Introduction
Chronic vascular pathological conditions (e.g., hypertension,
atherosclerosis, trauma, infection) promote localized release of protei-
nases and enzymes which break down the intact extracellular matrix
(ECM; e.g., elastin, glycosaminoglycans (GAGs)) within the adult ab-
dominal aortic walls [1,2]. Unfortunately, the major cell types in aorta,
i.e., smooth muscle cells (SMCs) and adventitial fibroblasts, are limited
in their ability to repair, replace or regenerate the degraded vascular
matrix, which often results in progressive weakening and burgeoning of
blood vessel diameter (> 50% increase relative to healthy vessel) – a
condition clinically termed as abdominal aortic aneurysm (AAA). AAAs
are also typically characterized by the presence of innate and adaptive
immune cells (e.g., macrophages, T-cells, neutrophils, lymphocytes)
which release abnormal levels of cytokines and matrix metalloprotei-
nases (MMPs) to exacerbate the breakdown of elastic fibers and other
matrix proteins [3,4]. This, in turn, disrupts the signaling between
elastic fibers and SMCs, promotes SMC apoptosis, and weakens elasti-
city in blood vessel walls, to permanently alter the mechanical prop-
erties and native microenvironment of the vessel wall [5,6].
Among the major ECM components native to blood vessels, col-
lagen, GAGs and elastin play an important role in regulating cell ad-
hesion, anchoring, proliferation, and migration [4,7]. They also reg-
ulate blood vessel homeostasis by supporting axial and circumferential
T
loadings and conferring anti-thrombogenic properties [8]. These ECM
molecules are synthesized, crosslinked, and deposited as mature matrix
fibers by SMCs and adventitial fibroblasts within the aorta. While the
turnover of collagens and GAGs is maintained even through adoles-
cence, elastic matrix fiber deposition primarily occurs only during de-
velopmental stages and preserved throughout the adult life (elastin
half-life is ~74 years) [9]. Since healthy elastic fibers play critical
biochemical and biomechanical roles in maintaining vessel home-
ostasis, abnormalities in elastin formation due to genetic defects or
elastin degradation due to diseases could result in peptides formation,
which obfuscates the beneficial role of intact elastic fibers [10,11].
Given the limitations of existing surgical (e.g., endovascular an-
eurysm repair, open surgery), pharmacological (e.g., anti-inflammation
agents, beta-blockers, statins) and preservation (e.g., MMPs inhibition,
TIMPs delivery, elastases suppression) interventions for comprehensive
AAA treatment [9,12–15], ECM (specifically elastin) repair and re-
generation approaches focusing on tissue-engineered grafts, stem cells,
3D scaffolds, bimolecular cues, biomechanics, and their combinations,
are being explored [16,17]. While the phenotype and gene expression
of ECM proteins synthesized by healthy Hu-SMCs has been reported
[18–21], similar outcomes from their AAA-counterparts are unknown.
Specifically, the baseline levels of matrix proteins synthesized and de-
posited by human AAA-SMCs, changes in their phenotype and gene
expression, the cytokines and chemokines released, their stiffness le-
vels, and the responses to exogenous biomolecular cues, remains un-
explored. Such information is critical for understanding the disease
etiology and identify effective pharmacological, tissue engineering and
regenerative medicine strategies to repair and regenerate elastin in AAA
vessels.
We have recently reported on the benefits of delivering exogenous
nitric oxide (NO) cues via S-nitrosoglutathione (GSNO), to cell pro-
liferation and ECM deposition by adult human aortic SMCs (Hu-SMCs)
within 3D biomimetic cocultures with adult human endothelial cells
(Hu-ECs) [22]. Such NO delivery from GSNO was also shown to sup-
press cell proliferation and stimulate mRNA expression and synthesis of
tropoelastin and lysyl oxidase (LOX) in chick aortic SMC cultures [23].
Physiologically, NO is produced from L-arginine and oxygen by en-
dothelium nitric oxide synthases (eNOS) [24], and exogenous NO
exposure inhibits eNOS activity [25,26] and induces S-nitrosylation of
cysteine residues [27]. NO donors and eNOS gene transfer were shown
to inhibit SMC proliferation in vitro, resulting in a delay in cell cycle
progression but not apoptosis [28–30]. NO delivered from the donor
compounds such as diethylenetriamine NONOate and S-nitro-N-acet-
ylpenicillamine inhibited elastase release and activity, and matrix re-
modeling by porcine pulmonary artery SMCs, by repressing ERK
phosphorylation [31,32]. These studies attest to the role of NO donors
and NOS in promoting elastogenesis at transcriptional- & translational-
levels, and attenuating inflammation within diseased aortic tissues.
This study is based on the hypothesis that exogenous NO delivery to
AAA-SMCs will inhibit inflammatory markers release, suppress cell
proliferation, promote elastic matrix synthesis, and enhance healthy
and contractile phenotype, thereby providing an attractive therapeutic
strategy to restore the lost functionality of AAA-SMCs and improve
vascular tone. We first investigated the changes in transcription levels
of AAA-SMC genes, involved in the pathological progression of this
disease. Next, we assessed the in vitro baseline levels of cell prolifera-
tion, phenotypic and genetic expression, ECM and biomolecular
(elastin, sulfated glycosaminoglycans (sGAGs), hyaluronan (HA), LOX,
desmosine, inducible nitric oxide synthase - iNOS) synthesis and de-
position, release of cytokines/chemokines/MMPs/TIMPs, and bio-
mechanical characteristics of human AAA-SMCs. Similar outcomes from
healthy Hu-SMCs were assessed under identical culture conditions for
comparison. Finally, the response of AAA-SMCs to exogenously-deliv-
ered NO cues was evaluated and compared to their healthy counter-
parts, to investigate the utility of delivering exogenous NO for AAA
treatment.
2. Materials and methods
2.1. Population study
LILAS was a case-control study that enrolled 42 men, some with
AAA, who needed a vascular surgery or endovascular treatment at the
Lille University Hospital Centre (Lille, France) between September
2003 and July 2005 [33]. Case patients were considered eligible if the
AAA diameter, measured by abdominal ultrasound exceeded 50mm, or
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Fig. 1. (A) A sample AAA tissue (n=20 patients)
used for SMC cultures. Representative phase-contrast
microscopy of SMCs obtained by explant from
human AAA biopsies. Western blot analysis of SMC
for fibronectin, meta-vinculin (160 kDa), vinculin
(116 kDa) and α-smooth muscle actin (α-SMA). Scale
bar: 100 μm. (B) mRNA expression ratio of genes
(2−dCt; normalized to house-keeping genes) in SMCs
derived from AAA (n=12) patients, potentially in-
volved in matrix degrading processes in AAA, as
determined by RT-PCR.
microscope equipped with Hamamatsu camera and image acquisition
software. At least ten images per cell type were processed using ImageJ
(NIH) to quantify the perimeter and area of each cell type.
Two sets of cultures were performed in parallel. 3D collagen gels
were prepared by mixing collagen stock solution (type 1, rat-tail de-
rived, BD Biosciences, Bedford, MA, USA) with a mixture of 10×PBS,
1M NaOH and deionized water. For 3D cultures, SMCs were mixed in
collagen gels at a density of 104 cells per well in 48-well plates. The
cultures were placed in a humidified incubator (37 °C, 30min) to
polymerize the collagen gels. For 2D cultures, collagen-coated 24-well
tissue culture plastic plates were seeded with 104 cells per well. Both
healthy- and AAA- SMCs were plated from passages 4–6. GSNO dose
used in this study was identified from our previous study [22] where a
range of GSNO doses were tested to evaluate their effects on ECM
synthesis and deposition. Media was changed once every two days and
the spent medium was pooled over the 21-day culture and stored at
−20 °C for further biochemical analyses. Similarly, cell matrix layers at
the end of 21 days were trypsinized and processed for biochemical
assays.
2.5. Biochemical assays
At the end of 21 days, the amounts of various protein types released
into the pooled media or deposited within cell matrix of 2D and 3D
cultures were quantified as detailed earlier [22]. Individual biochem-
ical assays were performed on AAA-SMC cultures to quantify total
protein (BCA Kit Assay; Sigma-Aldrich), elastin (Fastin assay; Accurate
Scientific Corp, Westbury, NY), sulfated glycosaminoglycans (sGAGs;
Kamiya Biomedical Company, Seattle, WA), and HA (hyaluronan en-
zyme-linked immunosorbent quantitative assay; Echelon Biosciences
Inc., Salt Lake City, UT) amounts. The protein amounts within cells was
not separated from the total protein quantified within cell layers. The
non-cellular protein contribution to the BCA assay (from collagen gels
in which the cells were cultured) was accounted by estimating the
protein content in 2mg/mL collagen gels and collagen-coated 2D cul-
tures without cells, and deducting from the measured total protein
amounts reported in test cases. Although other ECM proteins such as
collagens might be released and deposited by SMCs, their amounts were
not assessed here. SMC proliferation was quantified using a fluoro-
metric assay detailed earlier [22], to quantify the amount of DNA
Table 1
Baseline characteristics of the study population in AAA group.
AAA: aortic abdominal aneurysm; CAD: coronary artery disease;
MI: myocardial infarction; ACS: acute coronary syndrome;
PTCA: percutaneous transluminal coronary angioplasty. Data
expressed as mean ± SD, where appropriate.
AAA(n= 24)
Age, years 68.0 ± 6.1
Male gender, % 24 (100)
Anthropometric data
Weight, kg 82.9 ± 11.6
Height, cm 173.8 ± 5.4
Body mass index, kg/m2 27.4 ± 3.7
Cardiovascular risk factors, n (%)
Current smoking 4 (17)
Past smoking 17 (71)
Hypercholesterolemia 14 (58)
Hypertension 15 (63)
Diabetes mellitus 4 (17)
Familial history of CAD 4 (17)
Personal history of CAD, n (%) Stable
Angina 2 (8)
MI or ACS 7 (29)
Coronary artery bypass 1 (4)
PTCA 4 (17)
History of stroke, n (%) 0
if it had increased more than 10 mm during the past six months and 
required initial surgical treatment (Supplementary Table 1). The study 
conformed to the principles outlined in the Declaration of Helsinki, 
ethics committee of the Lille University Hospital Centre (France) ap-
proved the study, and each patient provided written informed consent. 
Clinical data items were presented as mean ± SD, and frequencies 
with proportions as appropriate. Statistical significance was assigned at 
p < 0.05.
2.2. Isolation of human AAA-SMCs
Aortic samples (Fig. 1A) were obtained for 20 of the 24 AAA pa-
tients and SMCs were isolated from all the 20 AAA tissue samples. In-
dividual cultures of AAA-SMCs were established for each patient by 
dissection of a residual segment of abdominal aorta and then cutting 
out the media into 1–2 cu.mm pieces and culturing them on type 1 
collagen coated dishes (rat tail-derived, BD Biosciences, France) in 
medium 231 supplemented with smooth muscle growth supplement 
(Cascade Biologics, France) and antibiotics (50 μg/mL streptomycin, 50 
U/mL penicillin; Sigma-Aldrich). SMCs were characterized by Western 
blot analysis. Twenty microgram fractions of cell lysates were separated 
by SDS-PAGE (9% polyacrylamide), transferred to Hybond C mem-
branes (GE Healthcare, France) and blotted with antibodies against α-
smooth muscle actin (α-SMA) (1A4, Dako, 1:5000), fibronectin (E3A, 
Sigma-Aldrich, 1:3000), and vinculin/meta-vinculin (hVIN-1, Sigma-
Aldrich, 1:400). The blots were subsequently washed in PBS-Tween 20 
and incubated with appropriate secondary antibodies (peroxidase-
conjugated anti-mouse IgG, GE Healthcare) at a dilution of 1:5000. The 
blots were then washed three times in PBS-Tween 20 for 15 min, in-
cubated with enhanced chemiluminescence reagents (GE Healthcare), 
and exposed to a radiographic film and scanned with an Imagescanner® 
(GE Healthcare). AAA-SMCs were subsequently passaged with Medium 
231 (Life Technologies).
2.3. Transcriptomic analysis of human AAA-SMCs
Changes in SMCs were validated for selected genes with qRT-PCR. 
RNA samples isolated from SMCs were converted to cDNA with an in 
vitro reverse transcription reaction. These cDNA were used as templates 
for Taqman qRT-PCR with ABI Assays-on-Demand on an ABI Prism 
7900 sequence detection system. The specific assays were designed by 
TaqMan® Gene Expression Assays (Applied Biosystems) and used Hs 
00199841-m1 (ADAMTS 5), Hs 00199836-m1 (ADAMTS 8), Hs 
00166915-m1 (renin), Hs 00174179-m1 (ACE1), and Hs 00377632-m1 
(L-cathepsin). All samples were run in triplicate, with GADPH 
(Hs99999905_m1) and Cyclophilin A (Hs99999904_m1) as internal 
controls to normalize transcript abundance (2−dCt method). Triplicates 
were averaged to calculate an expression value for each sample.
2.4. Human AAA and healthy aortic SMC cultures
AAA-SMCs derived from one patient (details in Table 1) were in-
vestigated further using biochemical and biomechanical analysis to 
establish the baseline. Healthy adult abdominal aortic Hu-SMCs were 
obtained from Life Technologies Corp. (Carlsbad, CA, USA) and pas-
saged using Medium 231 (ThermoFisher Scientific, USA). AAA-SMCs 
were cultured on 2D collagen-coated (50 μg/mL) substrates or within 
3D collagen hydrogels (2 mg/mL; pH ~ 7.2). Results from 2D substrates 
will help establish the baseline values, while cultures in 3D gels will 
provide more physiological-mimic microenvironment. Cells were cul-
tured for 21 days in SMC media, containing 100 nM GSNO (Sigma, 
Saint-Louis, MO, USA), a NO donor. Control cultures received no GSNO 
(termed 0 nM). The culture media contained recombinant human in-
sulin-like growth factor-I (2 μg/mL) and glucose (D-Glucose; levels un-
known). Healthy and AAA-derived SMCs were imaged at random lo-
cations during passaging using a Zeiss Axiovert A1 fluorescence
iNOS expression within healthy and AAA-SMCs, in both 2D and 3D
cultures, in the presence or absence of GSNO, was semi-quantitatively
evaluated using Western blot analysis as we detailed elsewhere [22]. To
optimize loading sample volumes for SDS/PAGE Western blot, cell
pellets from respective cultures were assayed using a DC protein assay
kit (Bio-Rad Labs). The protein bands were detected using a primary
polyclonal antibody for the iNOS protein (Abcam), using SMC-alpha
actin (Abcam) as the loading control, and the bands were visualized
using chemiluminescence method and quantified using ImageJ.
2.10. TIMP-1 assay
TIMP-1 amounts released by healthy and AAA-SMCs into the pooled
media, in the presence or absence of GSNO, were quantified using
Human TIMP-1 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN).
Spent media (supernates) from the cell cultures in 2D or 3D were
pooled and stored at −20 °C and loaded onto a 96-well polystyrene
microplate coated with a monoclonal antibody specific for human
TIMP-1. Post-incubation (2 h, RT) on a horizontal orbital shaker, the
bound proteins were incubated with human TIMP-1 specific horse-
radish peroxidase-linked polyclonal antibody (1 h, RT), exposed to a
chromogen solution containing tetramethylbenzidine for (30min, RT,
dark), and the reaction was stopped with 2 N sulfuric acid. Final solu-
tions were measured using Epoch BioTek microplate spectrophotometer
with absorbance at 450 nm. This assay has a range of 0.2–10 ng/mL in
cell culture supernates, with a sensitivity of 0.08 ng/mL.
2.11. Immunofluorescence labeling of cell layers
AAA-SMCs were cultured on glass chamber slides (104 cells/well)
for 21 days in the presence or absence of 100 nM GSNO, and the cell
layers were fixed in cold methanol, washed with PBS, blocked with PBS
containing 5% v/v goat serum (ThermoFisher Scientific) and im-
munolabeled with rabbit anti-human polyclonal antibodies against
elastin (1:100 v/v dilution, Abcam), fibrillin-1 (1:100 v/v dilution,
Bioss Antibodies), fibulin-4 (1:100 v/v dilution, Santa Cruz
Biotechnology), and fibulin-5 (1:100 v/v dilution, Santa Cruz
Biotechnology). Cell layers were washed with PBS and labeled with
Alexafluor 633 goat anti-rabbit secondary antibody; 1:1000 dilution,
ThermoFisher Scientific). The cell layers were washed with PBS and
mounted with Vectashield containing the nuclear stain 4′,6-Diamidino-
2-Phenylindole, Dihydrochloride (DAPI; Vector Laboratories,
Burlingame, CA). AAA-SMC layers treated with the secondary probe
alone (no primary antibody) served as negative controls. Cell layers
were imaged with a Leica SP8 confocal microscope (Leica Microsystems
Inc, Buffalo Grove, IL).
2.12. Atomic force microscopy (AFM) analysis
Healthy and AAA-SMCs were cultured in 35-mm laminin-coated
petri dishes and maintained at 37 °C throughout live-cell na-
noindentation assay, over a 60-min experiment each time, performed
using a MFP-3D-Bio AFM (Asylum Research, Santa Barbara, CA)
mounted on an inverted optical microscope (Nikon Eclipse Ti). Tip-less
AFM cantilevers (model Arrow TL 1, Nano World, nominal spring
constant ~ 0.03 N/m) were modified by attaching a 4.5 μm polystyrene
bead using epoxy [34]. The spherical bead indenter reduces the possi-
bility of destructive deformation of cell due to smaller local strains
applied [35], compensates for the x-y drift (usually < 1 μm), and
yields higher spatially-averaged measurement with minimal variability,
relative to conventional sharp-tip probes. The actual spring constant
was determined from a force-distance curve and using thermal cali-
bration method in a clean culture dish containing DMEM. Drifting
minimization and thermal/mechanical equilibrium of AFM was
achieved by submerging probe in cell medium for stabilization. For
each experiment, at least 30 cells were randomly selected, indented
between nuclei and cell edges, and 150–200 force curves were obtained
synthesized over the 21 days. Similarly, LOX functional activity was 
quantified using a fluorometric assay (AmplexRed® Assay; Molecular 
Probes, Eugene, OR).
2.6. Desmosine bioassay
The amount of desmosine produced and released by AAA-SMCs and 
healthy SMCs into the pooled media was quantified using a sandwich 
enzyme immunoassay technique (Human Desmosine ELISA Kit; 
MyBioSource, Inc., San Diego, CA). The desmosine bioassay has a de-
tection range of 0.1–10 ng/mL and a sensitivity of 0.039 ng/mL. Briefly, 
aliquots of samples and standards were incubated in a 48-strip-well pre-
coated with desmosine-specific antibody, and the bound desmosine was 
serially-tagged with biotin-conjugated DES-specific antibody and 
avidin-conjugated horseradish peroxidase, with intermediate washings 
after every step. Finally, desmosine amounts in each sample were as-
sessed calorimetrically based on the intensity of color generated within 
a substrate solution in proportion to the respective DES amounts.
2.7. Real-time PCR analysis of SMCs
For RT-PCR analysis, AAA-SMCs and healthy SMCs were cultured in 
parallel on 2D collagen-coated substrates or within 3D collagen gels and 
exposed to 100 nM GSNO for 5 days to induce changes in gene ex-
pression, and GSNO-free cultures served as controls. Total RNA was 
extracted from SMCs using RNAqueous®-Micro total RNA isolation kit 
(Life technologies) according to the manufacturer's instructions. The 
RNA concentration of each sample was determined using a NanoDrop 
ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE). The 
RNA was reverse-transcribed to cDNA using the high-capacity cDNA 
reverse transcription kit with RNase inhibitor (Life Technologies) ac-
cording to manufacturer's instructions. Gene expression in SMCs was 
quantified using TaqMan® gene expression assays (Applied Biosystems), 
and TaqMan® Gene expression master mix for each target using the ABI 
7500 Real-time PCR System (Applied Biosystems, Forest City CA) lim-
ited to only 40 cycles. The following genes (details in Supplementary 
Table 2) were analyzed: lysyl oxidase (LOX, Assay ID: 
Hs00942480_m1), elastin (ELN, Assay ID: Hs00355783_m1), fibrillin 1 
(FBN1, Assay ID: Hs00171191_m1), and inducible nitric oxide synthase 
2 (NOS2, Assay ID: Hs01075529_m1). To identify relative differences in 
the levels of target genes, gene expression in AAA-SMCs was normalized 
to endogenous reference gene (18S, Assay ID: 4319413E) and further to 
corresponding expression in healthy SMCs, using the ΔΔCt method.
2.8. Cytokine/chemokine assays
Cytokine, chemokine, TIMP and MMP analyses were performed 
using Discovery Assays® (Eve Technologies, Alberta Canada), from 2D 
or 3D cultures of AAA-SMCs and healthy SMCs. Briefly, cell culture 
supernatants were collected from each well after 24 h, spun down at 
3000 g for 5 min, and stored at −20 °C. The supernatants were then 
processed using multiplexing LASER bead technology and processed on 
a dual-laser flow-cytometry system (Bio-Plex 200). The technology 
works by utilizing different combinations of red and infrared fluor-
ophore beads conjugated to specific antibodies targeted to the cytokine 
or chemokine of choice and read using a flow-cytometry based system. 
The quantity of the specific analyte generated was based off a series of 
standards set forth by the company. The assays performed include 
human focused 11-plex, human MMP 9-plex and TIMP 4-plex, to 
quantify the following analytes: GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-6, 
IL-8, IL-10, IL-12 (p70), MCP-1, TNF-α, MMPs-1, 2, 3, 7, 8, 9, 10, 12, 
13, and TIMPs-2, 3, 4.
2.9. Western blot analysis of iNOS
Table 1 summarizes the baseline characteristics of the 42 AAA
subjects. One-third of the AAA patients had hypertension, half had
dyslipidemia, 17% had diabetes mellitus, and 29% had family members
who had a history of heart disease (myocardial infarction and/or acute
coronary syndrome). The AAA case patients (n=24) had a mean
maximal external aortic diameter of 56.1 ± 11.3 mm (range:
46–95mm). Fewer AAA patients received ACE inhibitor treatment
(21% vs. 44%; Supplementary Table 1). None of the AAA patients took
non-steroidal anti-inflammatory drugs (NSAIDs).
3.2. Primary AAA-SMC cultures
SMCs migrated from AAA explants after 10 days and reached con-
fluence in one month. All the cultured AAA-SMCs had the same elon-
gated, spindle-shaped morphology, and at confluence all cultures as-
sumed a hill-and-valley pattern that was maintained throughout
subcultures (Fig. 1A). Protein expression profiles determined by Wes-
tern blot analysis (Fig. 1A) showed that all the cultures from patient
groups expressed α-SMA, vinculin and meta-vinculin, indicating the
presence of differentiated SMCs. Fibronectin, a component of basement
membrane, was also expressed indicating a proliferative and secretory
SMC phenotype. RT-PCR analysis (Fig. 1B) indicated that mRNA ex-
pression of three genes appeared to be significantly down-regulated in
SMCs from AAA patients: ACE (angiotensin converting enzyme),
ADAMTS 5 and ADAMTS 8. The plots of individual mRNA expression
for these three genes (normalized to house-keeping genes) shows the
variability, with ADAMTS8 being the most suppressed.
3.3. AAA-SMC proliferation and dimensions
Despite similar morphologies within 2D cultures, the area and
perimeter of AAA-SMCs within 2D cultures were significantly higher
compared to their healthy counterparts (Fig. 2A; p < 0.01 in both
cases). The phenotype of AAA-SMCs was confirmed by staining for α-
actin in monolayer cultures, with more than 98% positive-stained cells.
In general, AAA-SMC proliferation is significantly lower in 3D gels
Fig. 2. (A) Representative phase-contrast images of adult healthy Hu-SMCs and AAA-SMCs cultured in this study. Significant differences in average cell area and
perimeter were noted between the two cell types. Data shown represents mean ± standard error in respective cases. Scale bar: 200 μm. (B) Fold increase in AAA-
SMC density within 2D and 3D cultures, in the presence or absence of exogenous 100 nM GSNO. Data shown represents mean ± standard error of cell count after 21
days of culture, normalized to initial seeding density (n=3/condition). Cell densities were quantified using a fluorometric assay detailed earlier (C) Fold-changes
(vs. GSNO-free controls). in total protein, elastin, sGAG, and HA, deposited within cell matrix or released into pooled media, by human AAA-SMCs, in 2D and 3D
cultures, in the presence of 100 nM GSNO. The total protein amounts were quantified using a BCA protein assay, elastin amounts using a Fastin Assay kit, sGAG
amounts using a quantitative dye-binding sGAG assay kit, and HA amounts using a hyaluronan enzyme-linked immunosorbent quantitative assay. Quantitative
results were obtained from cell matrix layers or pooled media after 21 days of culture and normalized to cell count within respective cases (n= 6/condition). Data
were analyzed using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and differences deemed significant for p < 0.05
between respective cases. Data shown represents mean ± standard error in respective cases. The absolute amounts of each protein per cell were listed in Table 2 for
baseline purposes.
at random locations on each cell in force-volume mode, at a rate of 
0.25 Hz with approach/retraction velocity of 2.5 μm/s. Using Hertz's 
contact model [ (4F E R )δ /3(1= −3 2)μ ], Young's modulus was de-
termined from these force curves, where F is the indentation force, E is 
the Young's modulus, μ is the Poisson's ratio (0.5 for cells), R is radius of 
spherical bead attached to cantilever and δ is the indentation depth 
(300–400 nm) [35]. The analysis of force-indentation curves was au-
tomated using Igor Pro 6.37 software. The indentation data was ana-
lyzed assuming cells behave as linearly elastic at small strain regimes. 
The mean elastic modulus values were calculated for each cell from the 
elastic modulus heat maps generated over randomly-selected 
90 × 90 μm2 area, and then averaged across multiple cells for each 
culture condition group. From this data, the mean surface roughness 
(Ra) of each cell - characterized as the arithmetic mean of the devia-
tions in height from the line mean value, and the root mean square 
(Rq), were calculated [36]. Both Ra and Rq were obtained from ran-
domly selected areas (30 × 30 μm2) on the cell membrane. A two-tailed 
Student's t-test was applied to all the pairs of samples (untreated-treated 
cells) for statistical analysis and p < 0.05 were considered significant.
2.13. Statistical analysis
All biochemical data were obtained from three independent repeat 
experiments per case (n = 3 wells/case/experiment) and analyzed 
using one-way ANOVA followed by Tukey's HSD post-hoc testing, as-
suming unequal variance and differences deemed significant for 
p < 0.05. The data were assumed to follow a near-Gaussian distribu-
tion in all the cases, and the mean and standard errors were calculated 
accordingly.
3. Results
3.1. Patients
cultures modestly enhanced matrix elastin yields in the absence and
presence of GSNO (0.5% and 0.8%, respectively). Thus, elastic matrix
yields improved by 10-fold in 3D cultures with the addition of GSNO,
similar in trend to that observed for the total protein amounts.
3.6. sGAG and HA synthesis
Adding GSNO to AAA-SMC cultures increased sGAG deposition in
matrix layers (2.73- and 1.52- fold, respectively) and in pooled media
(2.17- and 1.72- fold, respectively) within 2D and 3D cultures, per cell
(Fig. 2C), although the amounts were two orders of magnitude higher in
pooled media. Compared to 2D cultures, 3D cultures appeared to pro-
mote sGAG release into pooled media or deposition within cell layers,
per cell (Table 2). sGAG yield (ratio of matrix sGAG to the total sGAG
produced) within 2D AAA-SMC cultures indicated that matrix yields
were 0.9% and 2.3% in controls and GSNO-additive cultures, respec-
tively. However, 3D cultures did not show any enhancement of matrix
sGAG yields, in the presence or absence of GSNO.
GSNO addition modestly increased HA deposition in cell matrix per
cell in both 2D and 3D cultures (1.41- and 1.35- fold, respectively;
Fig. 2C), with similar increases in HA release into the pooled media.
When AAA-SMCs were cultured in 2D, the matrix HA yields (ratio of HA
deposited in matrix to the total HA produced) were 1.6% and 1.7%
within controls and GSNO additive-cultures, respectively. However, 3D
cultures modestly increased matrix HA yields, in the presence or ab-
sence of GSNO (2% and 1.9%, respectively).
3.7. LOX enzyme activity
While GSNO addition to 2D cultures did not induce a significant
change in LOX activity within cell matrix, it induced a 2.55-fold in-
crease within 3D cultures (Fig. 3A; p < 0.01). LOX activity in matrix
within 3D cultures was significantly higher (2.2-fold; p < 0.01) than
that in 2D cultures. LOX activity within pooled media from 3D cultures
was 13.5-fold higher than that in 2D cultures in the absence of GSNO.
Although adding GSNO to 3D cultures did not enhance LOX activity
compared to controls, it significantly increased LOX activity within 2D
cultures (14.9-fold; p < 0.01).
3.8. Desmosine crosslink density
In healthy SMC cultures (Fig. 3B), desmosine levels were higher in
2D cultures than in 3D cultures (p < 0.01), and GSNO offered no ad-
ditional benefit in both 2D and 3D cultures. However, in AAA-SMC
cultures, desmosine levels were significantly higher in controls com-
pared to GSNO-receiving cultures (p < 0.01), in both 2D and 3D. The
basal levels of desmosine by AAA-SMCs remained unaltered in both 3D
and 2D cultures. Finally, significant difference in desmosine levels were
noted between healthy and AAA derived SMCs, in 3D cultures receiving
Amounts of various proteins deposited in cell matrix or released into pooled media by healthy and AAA human aortic SMCs, per cell, over a 21-day period, within 2D
or 3D cultures, in the presence or absence of 100 nM GSNO. Data shown here represents the average of at least n= 6/case. Data for the healthy Hu-SMCs were from
our previous publication [22].
GSNO
dose
(nM)
Fold-increase in
proliferation,
compared to initial
seeding
Total protein
amounts (μg)
Elastin (ng) sGAGs (ng) HA (pg) LOX functional
activity (pM)
Cell
matrix
Pooled
media
Cell matrix Pooled
media
Cell matrix Pooled
media
Cell matrix Pooled
media
Cell
matrix
Pooled
media
3D cultures Healthy
Hu-SMCs
0 3.2 0.13 2.02 ND 7.06 ND 16.7 0.21 2.07 69 70
100 2.03 0.12 3.12 1.31 29.9 0.49 7.08 0.5 3.2 370 1610
3D cultures Hu-AAA-
SMCs
0 2.05 0.27 37.9 <0.01 0.17 < 0.01 0.036 0.57 27.6 0.1 2.76
100 1.3 0.83 52.7 <0.01 0.26 < 0.01 0.063 0.77 40.7 0.27 3.1
2D cultures Hu-AAA-
SMCs
0 2.8 0.016 16.8 <0.01 0.15 < 0.01 0.015 0.36 22.8 0.02 0.18
100 2.1 0.042 34.6 <0.01 0.177 < 0.01 0.034 0.51 29.7 0.03 2.5
ND: Not detectable within assay limits (i.e., < 1 pg/cell amounts).
compared to their 2D counterparts (Fig. 2B). Addition of GSNO sig-
nificantly suppressed SMC proliferation in 3D gels with a similar trend 
in 2D counterparts.
3.4. Total protein synthesis
Protein synthesis and release by AAA-SMCs has not been reported 
earlier. The total protein synthesized by AAA-SMCs, in 2D and 3D 
cultures, in the presence or absence of GSNO, was quantified as two 
separate components (Fig. 2C): protein deposited in the cell matrix 
(termed matrix here) and protein released into the pooled media 
(termed media here). A significant increase in the total protein de-
posited in cell matrix was observed with GSNO addition, in both 2D 
(2.58-fold) and 3D (3.1-fold) cultures. Total protein deposited in cell 
matrix within 3D cultures was significantly higher than that in 2D 
counterparts (p < 0.01), in the presence or absence of GSNO (16.4-fold 
and 19.8-fold, respectively). GSNO stimulated significant increase in 
the total protein released into the pooled spent media in 3D cultures 
(p < 0.01 vs. 2D). The amounts of protein in pooled media were at 
least two-orders of magnitude higher than in matrix, in all conditions. 
This study established the baseline for the total protein amounts re-
leased and deposited by adult human AAA-SMCs in 2D and 3D cultures 
(actual amounts provided in Table 2), in the absence of any stimulation. 
However, less than 2% of total protein produced by AAA-SMCs was 
deposited as matrix within cell layers, suggesting that additional ap-
proaches are required to coacervate the protein into matrix form. 
Compared to healthy SMCs (Table 2; Supplementary Fig. 1), the total 
protein deposited within 3D cell layers or released into the spent media 
by AAA-SMCs was significantly higher (i.e., 2-fold and 19-fold, re-
spectively) even in the absence of GSNO. GSNO stimulated a 7-fold 
increase in protein deposition within matrix layers and a 17-fold in-
crease in protein release within pooled media by AAA-SMCs within 3D 
cultures, compared to Hu-SMCs (Supplementary Fig. 1).
3.5. Elastin synthesis and deposition
The total elastin synthesized by AAA-SMCs (Fig. 2C; Table 2) was 
quantified as that deposited in the cell layers (i.e., matrix elastin) or 
released into the pooled media (i.e., tropoelastin). The benefits of 
exogenous NO to elastin deposition in cell matrix appeared to be de-
pendent on the substrate type. Compared to GSNO-free controls, sig-
nificantly higher matrix elastin was deposited within 3D cultures with 
GSNO addition, although matrix elastin deposition decreased in 2D 
cultures. GSNO stimulated tropoelastin release only within 3D cultures, 
although the amounts were two-orders of magnitude higher than matrix 
elastin (Table 2).
The matrix elastin yields (ratio of matrix elastin to the total elastin 
produced) within 2D AAA-SMCs cultures were 0.4% and 0.08% with 0 
and 100 nM GSNO additive-cultures, respectively. However, 3D
Table 2
no GSNO (p < 0.001).
3.9. iNOS expression and TIMP-1 release
To test if exogenously-delivered NO influenced iNOS protein ex-
pression in AAA-SMC cultures, Western blot analysis was performed
(Fig. 3C; bands in insert). The basal level of iNOS expression (2D con-
trol cultures) was significantly higher in AAA-SMCs compared to
healthy counterparts (p < 0.05). It was found that GSNO addition to
2D cultures significantly promoted iNOS protein expression in healthy
SMCs, but not in 3D cultures. Expression of iNOS by AAA-SMCs, on the
other hand, was not modified by 2D or 3D cultures, and/or by GSNO
addition.
No significant difference in TIMP-1 release was noted between 2D
and 3D AAA-SMC cultures in controls (Fig. 3D). GSNO induced a 2.4-
fold increase in TIMP-1 release in 3D cultures. While the basal levels of
TIMP-1 release was significantly lower in AAA-SMCs compared to adult
healthy aortic SMCs in 3D cultures [22], the levels were similar in the
presence of 100 nM GSNO.
3.10. Elastin, iNOS, LOX and fibrillin gene expression
Elastin (ELN) gene expression in AAA-SMCs, both in 2D and 3D
cultures, in the presence or absence of NO cues, was significantly lower
compared to healthy SMCs (Fig. 4A). Such inhibited elastin gene ex-
pression levels in AAA-SMCs, compared to healthy SMCs, was in
agreement with their respective protein expression levels of matrix
elastin (Table 2). Similarly, within AAA-SMCs, elastin gene expression
was significantly lower in 2D compared to that in 3D, in agreement
with their protein expression levels. Surprisingly, elastin gene expres-
sion was significantly lower after GSNO addition, in contrast to tro-
poelastin and matrix elastin produced by these cells (Fig. 2, C-D).
The iNOS gene expression of healthy and AAA-SMCs were similar in
2D and significantly increased in 3D cultures for AAA-SMCs (Fig. 4A).
Adding GSNO had no significant effect on iNOS gene expression in
AAA-SMC cultures, suggesting that AAA-SMCs are sensitive to signaling
from exogenous NO cues, similar to their healthy counterparts. LOX
gene expression was significantly higher (6–10 -fold in 2D and 3D
cultures, respectively) in AAA-SMCs compared to healthy SMCs, al-
though adding GSNO suppressed such elevated levels (Fig. 4A), in
contrast with the LOX functional activity (Fig. 3A). The baseline levels
of fibrillin-1 (FBN) gene in AAA-SMCs was significantly higher com-
pared to their healthy counterparts, although such expression levels
were significantly downregulated in 2D AAA-SMC cultures with GSNO
addition (Fig. 4A).
3.11. Release of cytokines, chemokines, MMPs, and TIMPs
We quantified the baseline levels (2D - 0 nM) of cytokines, chemo-
kines, MMPs and TIMPs released by healthy Hu-SMCs [Supplementary
Fig. 2 (A:< 10 pg/mL; C:< 250 pg/mL; E:< 40 ng/mL)] and adult
human AAA-SMCs [Supplementary Fig. 2 (B:< 10 pg/mL;
D:< 250 pg/mL; F:< 40 ng/mL)]. Their levels in 3D cultures, and in
the presence of 100 nM GSNO were also shown in respective panels.
The analytes released by SMCs were plotted on a log-scale using a
heatmap function (Fig. 4B). MMPs and TIMPs were the most highly-
expressed analytes compared to the cytokines (e.g., ILs). Benefits of
GSNO delivery in healthy SMC cultures (both 2D and 3D), appeared
marginal with no significant modulation in ILs and MMPs release but
significant increase in TIMPs release. However, in 3D AAA-SMC cul-
tures, GSNO suppressed the release of several analytes (e.g., IFN-γ,
MMPs-8, 9, 12, IL-8) compared to all other conditions, and some ana-
lytes were undetectable in most conditions (IL-1β and TNF-α). A ten-
fold increase in IL-6 release by AAA-SMCs was found compared to
healthy counterparts. Variations in analyte concentrations were ob-
served across samples cultured in 2D vs. 3D environments; for instance,
SMCs in 2D cultures had higher concentrations of MMP-2, MMP-12,
TIMP-2, TIMP-3, and MCP-1, in both healthy and AAA-SMC cultures. In
general, cytokine and MMPs production in both cell types appeared to
be regulated by GSNO presence as well as culture substrate (2D vs. 3D).
3.12. Immunofluorescence labeling of matrix proteins
AAA-SMCs deposited detectable matrix elastin and fibulins-4 and 5
within 2D cultures over the 21-day period within control cultures
(Fig. 5). However, fibrillin-1, critical for matrix elastin coacervation
Fig. 3. (A) Fold-changes in LOX enzyme functional
activity within cell matrix and pooled media of AAA-
SMC cultures, quantified using an Amplex Red®
fluorometric assay and quantified per cell. Cells were
exposed to 100 nM GSNO while controls received no
GSNO. The absolute amounts of LOX functional ac-
tivity per cell were listed in Table 2 for baseline
purposes. (B) Desmosine levels in pooled media
collected from 2D/3D Hu-SMCs or AAA-SMC cul-
tures, over the 21-day period, in the presence or
absence of GSNO. (C) iNOS protein expression was
quantified from Western blot analysis. Re-
presentative bands are shown in the insert for com-
parison. iNOS protein expression by AAA-SMC cul-
tures was normalized to that in 2D GSNO-free
cultures of healthy SMCs. (D) Similarly, the release
of TIMP-1 into pooled media was quantified using a
TIMP-1 ELISA assay. GSNO (0 or 100 nM) was sup-
plemented to AAA-SMC cultures in 2D or 3D cultures
over 21 days. Data were analyzed using one-way
ANOVA followed by Tukey's HSD post-hoc testing,
assuming unequal variance and differences deemed
significant for p < 0.05. Data shown represent
mean ± standard error of quantified data and nor-
malized to cell count within respective cases (n=6
per condition). (For interpretation of the references
to color in this figure legend, the reader is referred to
the Web version of this article.)
and crosslinking, was undetectable around the periphery of most cells.
GSNO promoted deposition of matrix elastin, fibrillin-1 and fibulins-4,
5, compared to controls.
3.13. Cell mechanics using AFM
Single cell nanoindentation measurements were obtained to quan-
tify the elastic modulus (E) of live SMCs under different culture con-
ditions (Fig. 6; Supplementary Fig. 3). Representative phase-contrast
images (Supplementary Fig. 3), heat maps of elastic moduli (Fig. 6A),
and force-indentation curves (Fig. 6B) were shown for healthy and AAA
SMCs, in the presence or absence of GSNO. The average modulus of
elasticity for AAA-SMCs (17.41 ± 0.34 kPa) was significantly higher
(1.6-fold; p < 0.001) than for healthy SMCs (10.42 ± 0.29 kPa), in-
dicating an increase of stiffness in AAA-SMCs (Fig. 6C). Upon exposure
to GSNO, the average modulus of elasticity for healthy SMCs decreased
by 1.3-fold (healthy SMCs: 8.67 ± 0.25 kPa, p < 0.05; AAA-SMCs:
13.03 ± 0.35 kPa, p < 0.05). Cell roughness measurements showed
Fig. 4. (A) Lavik method (ΔΔCt method) was used for relative quantification of the fold changes in ELN, iNOS, LOX, and FBN genes in AAA-SMCs, after addition of
GSNO (0 or 100 nM) within 2D or 3D cultures for 21 days. The gene expressions obtained from qRT-PCR analysis within AAA-SMCs were first normalized to
housekeeping gene (18S) expression within respective cultures, and further normalized to respective gene expressions within healthy Hu-SMCs cultured under similar
conditions. Data were analyzed using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and differences deemed significant for
p < 0.05. Data shown represent mean ± standard error (n=6 independent data points per condition). (B) Heat map showing the amounts of cytokines, che-
mokines, and MMPs/TIMPs released by healthy and AAA SMCs, in 2D and 3D cultures, in the presence or absence of 100 nM GSNO, as measured using laser bead
immunoassay.
that AAA-SMCs were smoother than Hu-SMCs (Fig. 6D). GSNO addition
significantly increased cell surface roughness in Hu-SMCs (p < 0.01),
and nearly doubled the roughness in AAA-SMCs, compared to re-
spective controls. In the presence of GSNO, Hu-SMCs and AAA-SMCs
had no significant differences in their surface roughness.
4. Discussion
In this study, we compared the differences and behaviors of human
aneurysmal SMCs and their healthy counterparts regarding cell pro-
liferation, phenotypic and gene expression, transcriptomic analyses,
immunofluorescence imaging, biomechanical characteristics, and their
response to exogenously-delivered NO cues, as a therapeutic AAA
treatment.
Prior studies reported that adult human AAA-SMCs proliferated 4-
fold over 16 days [37], 5-fold over 21 days [38], or doubled every 5.3
days [39] in 2D cultures, which is significantly higher than that noted
in our study. AAA-SMCs proliferated significantly slower compared to
their healthy counterparts (Table 2), possibly due to diseased nature
and/or minor differences in the phenotype between donors. AAA-SMCs
synthesized and deposited more proteins in 3D cultures compared to
the healthy aortic SMCs. Our results highlight the increased ability of
aortic SMCs to proliferate, migrate and deposit ECM under diseased
vascular conditions [40].
Despite the prominent role of elastin in aortic tissue homeostasis
maintenance, quantification of elastin synthesized by human AAA-
Fig. 5. Representative immunofluorescence images of AAA-SMC layers in 2D cultures, with or without GSNO, stained with respective primary antibodies for elastin,
fibrillin-1, fibulin-4 and fibulin-5, and counterstained with DAPI for cell nuclei. A significant increase in the expression of all the proteins was noted in the presence of
100 nM GSNO. Scale bar: 100 μm. For each treatment condition, at least three independent cell layers were imaged, with six random regions captured in each cell
layer.
Fig. 6. (A) Representative force maps of healthy Hu-SMCs (left panels) and AAA-SMCs (right panels) treated with 100 nM GSNO (lower panels). Background from
Petri dish was subtracted in these images. Representative force-indentation curves (B) and average Young's Modulus (C) of these cells cultured on 2D substrates, in
the presence or absence of 100 nM GSNO. The black dotted lines in (C) represent the arithmetic averages in respective cases, i.e., 10.33 ± 0.2624 KPa for untreated
Hu-SMCs (n=605), 8.674 ± 0.2491 KPa for Hu-SMCs receiving GSNO (n=550), 17.41 ± 0.3405 KPa for untreated AAA-SMCs (n=524), and
13.03 ± 0.3498 KPa for AAA-SMCs receiving GSNO (n=469). (D) The surface roughness parameters Rq and Ra in Hu-SMCs and AAA-SMCs, in the presence of
absence of GSNO. Data were analyzed using one-way ANOVA followed by Tukey's HSD post-hoc testing, assuming unequal variance and differences deemed
significant for p < 0.05. Data shown represent mean ± standard error (n=6 independent data points per condition).
where iNOS could barely be detected [50,53]. TIMPs-1, 2 regulate ECM
remodeling in vasculature by controlling the levels and activity of
MMPs. In agreement with our results, no significant differences in
TIMP-1 levels (Western blotting) within tissue sections isolated from
AAA patients and their healthy counterparts were observed [54].
Localized inflammation contributes to weakening of aorta due to
imbalances in ECM levels [55]. This has prompted research focused on
regulating the production of inflammatory molecules as a therapeutic
intervention in lieu of invasive surgical approaches [56]. The con-
centrations noted for MMPs/TIMPs in our study broadly falls in the
range reported by others and our previous work [22,37]. Given the
apparent differences in cytokine production between AAA and healthy
SMCs, our data supports the prevailing notion that cytokine stimulation
via paracrine or autocrine signaling may in turn modulate MMP acti-
vation [57]. Although it has been suggested that NO can influence the
production of some cytokines and chemokines [58], we did not see any
differences. In summary, our data is consistent with the inflammatory
patterns seen in AAA subjects and suggests that NO presence modulates
MMP production in a potentially therapeutic manner.
In addition to alterations in composition and functionality of vas-
cular endothelium and ECM, changes in cell stiffness might also con-
tribute to vascular tissue stiffness in AAAs, atherosclerosis and hy-
pertensive conditions. The stiffness (~30 kPa) of hypertensive aorta-
derived SMCs, as measured by AFM nano-indentation, was reported to
be two-fold higher than that of normal aorta (~14 kPa), and such
stiffness was mediated by cytoskeletal proteins [59]. Vascular SMCs
from old male monkeys exhibited much higher stiffness than their
younger counterparts (42 kPa vs. 13 kPa) [60]. The elastic modulus of
primary adult male rat arteriole-derived SMCs (~13.5 kPa) decreased
by 38% upon exposure to NO donor PANOate, most likely due to re-
modeling of actin cytoskeleton network [61]. Marfan vascular SMCs
were two-fold stiffer than healthy human SMCs, as measured by AFM,
most likely due to higher focal adhesion kinase protein and actin stress
fibers expression [62]. Here, we report for the first time on the stiffness
and surface roughness of human aortic SMCs from healthy and AAA
tissues, using AFM nano-indentation of live cells. Our results show that
(i) elastic modulus of healthy Hu-SMCs is lower than that in rats and
monkeys; (ii) human AAA-SMCs have higher stiffness and lower surface
roughness compared to healthy Hu-SMCs; and (iii) human AAA-SMCs
had significantly lower stiffness compared to hypertensive rat SMCs or
aged monkey SMCs.
Our results support our hypothesis that AAA-SMCs do respond to
exogenous NO cues to modulate cell proliferation and protein synthesis
in 3D cultures. We have recently shown that healthy Hu-SMCs produced
significantly higher amounts of tropoelastin and matrix elastin in the
presence of 100 nM GSNO, and that an optimal 100 nM GSNO promoted
sGAG deposition in matrix layers but not their release into the pooled
media, within 3D Hu-SMC cultures [22]. Our results along with perti-
nent literature suggest that exogenously-delivered NO donors (e.g.,
GNSO) release NO and other reaction products which stimulate iNOS
expression and endogenous NO release in healthy or aneurysmal SMC
cultures (Fig. 7). Such endogenous NO upregulates cGMP and thereby
protein kinase G (PKG) activation in SMCs [23,63], which in turn in-
duce cell relaxation (i.e., low stiffness) [64], suppress proliferation
[65], and stimulate elastic matrix synthesis [23]. This cascade of events
might contribute to enhanced SMC phenotype leading to improvement
in vascular tone and compliance in vivo, desired from a therapeutic
standpoint.
An increase in LOX functional activity within 3D AAA-SMC cultures
in GSNO presence (Fig. 3), and significantly higher deposition of fi-
brillar forms of elastic matrix-associated proteins such as fibrillin-1, and
fibulins- 4, 5 (Fig. 5), is highly encouraging for therapeutic tissue en-
gineering and in situ elastin regeneration. Increased levels of LOX
functional activity by exogenous GSNO might partially explain the in-
creases in matrix elastin, GAGs, and tropoelastin in 3D AAA-SMC cul-
tures. Similar increases in tropoelastin but not desmosine levels by
SMCs has received less attention. Tropoelastin, the precursor molecule 
to elastin, is encoded by a single copy of ELN gene in SMCs and fi-
broblasts. Tropoelastin amounts in human AAA extracts was reported to 
be 5-fold higher than that within normal human aortic tissues [21]. Our 
current study suggests that healthy Hu-SMCs produce higher amounts 
of tropoelastin and matrix elastin compared to their AAA counterparts. 
Adult human AAA-SMCs were shown to release ~10 pg of tropoelastin 
and deposited 0.02 pg of matrix elastin per cell in 2D cultures, in the 
absence of any external cues [38]. These amounts were significantly 
lower than what we observed, despite similarities in donor age, disease 
phenotype and culture duration. Numerous studies have shown that the 
significant changes in elastin protein within AAA ECM might be due to 
a related change in the gene expression levels [41,42]. Similar to our 
observations here, a down-regulation in elastin gene in AAA tissues was 
reported in a porcine model of induced AAA, compared to healthy 
counterparts [43].
Adult human AAA-SMCs in 2D cultures release significantly higher 
levels of GAGs (e.g., versican, perlecan, heparan sulfate, biglycans) 
compared to healthy aortic SMCs [44]. Although the various types of 
sGAGs released by AAA-SMCs were not individually identified in our 
study, we quantified the absolute amount of overall GAGs production 
by AAA-SMCs and found multifold increases in HA release into pooled 
media and deposition into matrix within AAA-SMC cultures. The 
combined amount of elastin and GAGs, in both pooled media and cell 
matrix, constitute a small fraction of the total matrix, suggesting that in 
addition to elastin and GAGs, numerous other proteins such as col-
lagens and proteoglycans, might have been released and deposited by 
AAA-SMCs within 2D and 3D cultures.
Such deposited elastin precursors are crosslinked in the presence of 
LOX enzyme, resulting in the formation of desmosine and isodesmosine 
linkages between lysine molecules on elastin molecules [45]. Thus, the 
final crosslinked elastic fibers typically have a microfibril sheath sur-
rounding the core elastin molecules. Additional stimulation such as 
alternate scaffold design, elastogenic scaffold material, exogenous LOX, 
and mechanical stimuli might be necessary to coax the AAA-SMCs to 
enhance matrix elastin yields. Although it is interesting to note that 
AAA-SMCs produce LOX which is functionally active, the levels of LOX 
functional activity within AAA-SMC cultures are at least two orders of 
magnitude lower than that quantified within healthy SMC cultures 
(Table 2), per cell. This difference might be due to the phenotypic 
differences between healthy versus AAA cells. Studies have shown that 
in addition to regulating vascular SMC phenotype (proliferation, mi-
gration), LOX also plays a primary role in ECM crosslinking such as 
collagens, elastin and GAGs [46]. However, under diseased conditions 
such as aneurysms, characterized by remarkable degradation and ECM 
remodeling, LOX activity and expression is significantly reduced. While 
it is not clear whether reduction in LOX levels contribute to the onset of 
the pathogenesis of these diseases or vice versa, numerous AAA-induced 
animal models demonstrate strong correlation between LOX expression 
reduction and disease progression [47]. Desmosine levels were detect-
able even in AAA-SMC cultures attesting to their ability to release 
components critical for crosslinked elastin deposition, although GSNO 
presence did not further stimulate these levels. Prior studies have 
shown that desmosine levels in healthy human arterial tissues were at 
least 9-fold higher than that in AAA segments [21], and reduced des-
mosine levels were reported in dissecting AAAs [48], suggesting the 
reason for diminished levels of mature, crosslinked elastin in AAA tis-
sues.
Although vascular NO plays an important role in regulating SMC 
functions such as vasodilation, survival, gene regulation, and quies-
cence phenotype, the harmful role of higher NO levels in the patho-
genesis of aneurysms has been documented [49–51]. Specifically, iNOS-
stimulated NO release from vascular SMCs was shown to participate in 
elastin degradation and disruption of vascular ECM [52]. Our ob-
servations agree with previous reports that experimental or human 
AAA-derived tissues had higher iNOS levels compared to control tissues
human and rat AA-SMCs were reported by others [21,66]. Higher
amounts of GSNO (> 100 nM) could possibly elevate desmosine levels
in 3D AAA-SMC cultures, which further enhances elastin crosslinking
and maturation.
The increased levels of TIMP-1 in AAA-SMC 3D cultures in the
presence of GSNO is encouraging in modulating further degradation of
vascular ECM by MMPs under diseased conditions. GSNO induced sig-
nificant increases in matrix elastin deposition in 3D cultures and re-
duced MMP-9 concentration by over 50% in all cases (2D/3D AAA-SMC
cultures), compared to healthy controls. Given that the upregulation of
MMP-9 is linked to the degradation of the aortic ECM, our results are
encouraging as they suggest a therapeutic benefit in the supplementa-
tion of exogenous NO [67]. Similar trend was noted for MMP-2 in
nearly all cases (excluding 3D AAA-SMC cultures). Similar patterns in
MMP downregulation were observed in eNOS gene–transfected cells
[68], and it has been suggested this pathway is regulated by guanylyl-
cyclase dependent and independent pathways [69]. NO appeared to
have little effect on TIMPs release across most cases. In agreement with
literature, we noticed significantly higher IL-6 levels by AAA-SMCs.
And finally, delivering exogenous NO significantly lessened AAA-SMC
stiffness and enhanced surface roughness, possibly via modulation of
cytoskeletal and surface proteins, respectively. We postulate that
changes in stiffness beginning at single cell level might contribute to
changes in vascular tone and functionality of aneurysmal vessels and
delivering GSNO could be explored as a therapeutic strategy. Taken
together, results confirm our hypothesis that exogenous NO delivery to
AAA-SMCs might help to promote protein synthesis, release and de-
position within 3D cultures, in addition to regulating their proliferation.
In conclusion, we established the baseline differences between adult
human AAA and healthy SMCs, in terms of their size, proliferation,
matrix and associated proteins synthesis and deposition, release of cy-
tokines/chemokines/MMPs/TIMPs, changes in gene expression of
elastogenic markers, and stiffness and roughness. We demonstrated that
exogenously delivering NO via GSNO offers an effective strategy to
enhance AAA-SMC functionality. Our current studies are geared to-
wards validating these phenotypic, genetic expression, and biomecha-
nical outcomes in multiple patient-derived AAA and healthy SMCs.
Nevertheless, these results help in designing tissue engineering and
regenerative medicine-based approaches, consisting of 3D scaffolds and
localized drug delivery options, specifically for in situ elastin re-
generation and remodeling to arrest aneurysm progression.
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